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Abstract
The increase in life expectancy has been accompanied by an escalation of 
 age-related disease incidence. Mild cognitive impairment (MCI) is a decline of 
cognitive function higher than expected for a certain age, but not severe enough 
to meet the criteria for dementia. Hypoxemia, smoking history, ageing and several 
comorbidities are risk factors for both chronic respiratory diseases and cognitive 
deficit. Up to 70% of patients with chronic obstructive pulmonary disease (COPD), 
obstructive sleep apnea (OSA) or idiopathic pulmonary fibrosis (IPF) have a form 
of cognitive impairment. Furthermore, a low neuropsychological performance is 
an independent predictor of disability and mortality in these populations. Efficient 
tools for cognitive assessment have been validated for these patients and should 
be used for better clinical outcomes. The physiopathological mechanisms, clinical 
impact and prevention strategies for cognitive dysfunction in chronic respiratory 
diseases will be detailed in the following chapter.
Keywords: cognitive dysfunction, hypoxemia, chronic obstructive pulmonary 
disease, obstructive sleep apnea, idiopathic pulmonary fibrosis
1. Introduction
In the era of antibiotics, vaccines and other medical innovations, life expectancy 
has increased worldwide, which has led to an enhanced prevalence chronic diseases. 
Only in the USA, the Department of Health and Human Services estimates that 
by the year 2040, 82.3 million Americans (21.7% of the population) will be over 
65 years of age [1]. Consequently, age-related illnesses that cause a significant mor-
bidity and mortality will become a rising public health problem. At the same time, 
there is an increase in the prevalence of multimorbidity, defined by the coexistence 
of two or more chronic pathologies in the same individual. Studies show that in 
individuals that are over 60 years old, the multimorbidity range is from 55 to 98% 
[2]. Multimorbidity is associated with functional decline, disability, poor quality of 
life, higher emergency care and hospitalizations rates, polypharmacy and increased 
healthcare costs, all of which are a great burden for society [3].
The concept of cognitive impairment has been carefully analysed in the last two 
decades, given the devastating consequences of this problem, mainly among elderly 
populations. Cognitive function can be divided into six large domains: language 
(verbal fluency and comprehension), learning ability and memory (work memory 
and memory-based tagging), attention, executive functions (planning and problem 
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solving), praxis (motor-ideative, ideative and visual constructive) and visuospatial 
function [4].
Mild cognitive impairment (MCI) is defined as a cognitive dysfunction more 
severe than normal age-related cognitive decline or education level, but not severe 
enough to significantly interfere with daily function [5]. MCI exceeds the “age-
related” decline in cognition healthy individuals experience but does not meet the cri-
teria for dementia. Furthermore, not all cases of MCI will progress towards dementia.
In the general population, studies have shown a prevalence of MCI between 10 
and 20% in older adults [5]. However, cognitive impairment is heavily underdiag-
nosed and undertreated by primary care physicians. There are several screening 
tools that can identify those with a high risk of MCI such as the Mini-Mental State 
Examination (MMSE), Montreal Cognitive Assessment (MoCA), Saint Louis 
University Mental Status Examination (SLUMS) or Rapid Cognitive Screen. Once 
the diagnosis of cognitive dysfunction is determined, it is essential to establish the 
aetiology and the contributing factors and to evaluate if there are any reversible 
causes. Every practitioner should be familiar with these questionnaires, especially 
MMSE, and should use them whenever they suspect a person of MCI.
Neuroanatomical structures and their function can be assessed by neuroimaging 
techniques. Computed tomography (CT) scan and magnetic resonance imaging 
(MRI) can analyse the brain structure and exclude conditions such as strokes, brain 
tumours or vascular malformation. The fluorodeoxyglucose positron-emission 
tomography (FDG-PET) scan, mostly used for research purposes, can evaluate the 
brain function and seems to be more sensitive than MRI in MCI diagnosis. This 
tool uses a radioactive glucose tracer which binds to highly active brain areas. The 
presence of hypometabolic areas in the temporal or parietal lobe is a sign of neuro-
degeneration. Subjects who develop these hypometabolic areas have a higher risk of 
progression from MCI to dementia [6, 7]. For research purposes, there are several 
biomarkers used for the diagnosis of MCI and dementia, but the lack of standard-
ization regarding optimal cutoff points limits their clinical utility [8].
There are well-established risk factors for developing MCI: age, male gender, 
family history of cognitive impairment, the presence of the apolipoprotein E 
allele, smoking and low educational level [9]. Moreover, one study, which aimed to 
determine if multimorbidity could be a risk factor for mild cognitive impairment 
and dementia, found that individuals who associate at least two of the following, 
hypertension, hyperlipidemia, coronary artery disease and arthritis, had a very 
high risk of MCI [3].
Recent studies showed that some chronic respiratory conditions, such as chronic 
obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA) or idio-
pathic pulmonary fibrosis (IPF), have an important impact on cognitive function. 
There are discrepancies regarding the reported prevalence of cognitive dysfunction 
among the conditions listed above, which can be explained by study design and 
limitations: diagnostic methods for cognitive impairment (psychometric tools 
or neuroimaging), small sample size or inappropriate control group, assessment 
moment (stable phase/exacerbation), the severity of the airflow limitation, pres-
ence of hypoxia and the use of long-term oxygen therapy. Multiple confounders can 
also contribute to the large variation of data regarding prevalence: age, education 
level, smoking history, comorbidities, etc.
2. Cognitive impairment in obstructive sleep apnea
Sleep apnea syndrome is a disorder of breathing during sleep, character-
ized by total or partial obstruction of the upper airways leading to hypoxia and 
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hypercapnia, plus increased respiratory effort [10]. These features produce micro-
awakenings that result in disruption of sleep and changes in neuronal activity. All of 
these are potential mechanisms for cognitive deficiency [11].
In adults, the prevalence of OSA increases significantly with age. Between 
30 and 49 years, 10% of men and 3% of women are diagnosed, increasing to 17 
and 9%, respectively, for 50–70 years [12] and with increasing prevalence among 
postmenopausal women [13]. These percentages are higher than those published 10 
years ago, due to the fact that obesity is increasing among the population of devel-
oping countries [14]. More worryingly, the true prevalence may be underestimated 
as many people with OSA remain undiagnosed.
Nighttime symptoms are noisy snoring, non-restful sleep, nocturia, sweating 
and dry mouth. One of the most common daytime symptoms in patients with 
OSA is daytime sleepiness. This greatly influences the quality of life and cognitive 
performance.
OSA has been associated with a wide range of psychological problems such as 
depression, anxiety, neurocognitive dysfunction, especially attention, alertness, 
memory and learning, phenomena due to fragmentation of sleep and intermittent 
hypoxemia [15–17]. Fragmentation of sleep, sleep deprivation and the association 
of excessive daytime sleepiness are proposed mechanisms that underlie cognitive 
impairment through their impact on attention [18, 19].
The exact prevalence of cognitive disorders and their severity due to multiple 
comorbidities with which this syndrome is associated is not known in adult patients 
with OSA.
2.1 Risk factors for cognitive deficits in OSA patients
There are numerous OSA comorbidities that can influence cognitive function, 
such as treatment-resistant hypertension [20], diabetes [21], COPD, conges-
tive heart failure, strokes [22], smoking [23] and alcoholism [24]. Also age, sex 
(male), obesity and the use of psychoactive drugs are considered independent 
risk factors [25].
Ageing itself causes decline in cognitive function, and the presence of OSA 
in these patients leads to further brain injury, with cognitive impairment being 
more obvious [26]. It is also known that smoking, through its damaging effects on 
blood vessels and circulation, increases the risk of dementia, both vascular and 
Alzheimer’s, as well as neurocognitive decline not associated with dementia [27].
Another important factor in the association of OSA with cognitive decline is, it 
seems, the genetic factor. Thus, studies show that the presence of apolipoprotein E4 
(ApoE4) is associated with an increased incidence of cognitive disorders [28].
High blood pressure is associated with cognitive decline, both when isolated and 
in the presence of metabolic syndrome, especially due to the presence of cardiovas-
cular risk factors [29].
Also, the presence of hypothyroidism in patients with OSA may accelerate 
cognitive decline, and current data are not sufficient to demonstrate whether the 
treatment ameliorates the decline phenomena [30].
Moderate alcohol consumption may protect against dementia, but significant 
alcohol consumption is associated with cognitive impairment, which is manifested 
by loss of memory, impaired personality and impaired judgement [24]. Alcohol 
intake before bedtime affects sleep architecture [31]. In addition, depending on the 
quantity, the instability of the upper airways may increase [32]. Thus, excessive 
alcohol use by patients with OSA may lead to more severe cognitive deficits.
Another common comorbidity of OSA is stroke, which, independently, is 
accompanied by a cognitive deficiency and even dementia. Studies show that up 
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to 30% of patients with stroke can develop dementia [33, 34]. And psychoactive 
medication, e.g. benzodiazepines, narcotics and barbiturates, can aggravate OSA 
and increase attention and alertness problems [35, 36].
Studies carried out over time have shown structural and functional changes 
in the brain, resulting in cognitive deficiency. There are studies that, by MRI 
techniques, have shown decrease of grey matter in the hippocampus; cerebellum; 
frontal, parietal and temporal lobes; as well as the anterior cingulate cortex [37–39]. 
Also, a decrease in the hippocampus was observed, which plays an important role 
in memory consolidation. The white matter changes reported by O’Donoghue et al. 
indicate that axonal or glial pathology is also present in OSA, consistent with other 
previous findings [40].
2.2 Physiopathology of cognitive impairment in patients with OSA
Studies on the cardiovascular effects of OSA have shown that the disorder results 
in changes in vascular structure and function, these changes being frequently 
encountered in other hypoxic populations [41]. It is assumed that hypoxia would 
have a direct effect on the neuropsychic in patients with OSA, with existing similar 
mechanisms in terms of cardiovascular changes and brain vessels. Hypoxia pro-
duces immediate vasodilation, being a protective mechanism to more efficiently 
distribute oxygen to the affected organ. Studies have shown that this protective 
mechanism does not exist in patients with OSA [42]. One potential reason why 
these patients do not have a response to hypoxemia is because they suffer from 
repeated episodes of hypoxemia (over five events/h) and desaturation, not just a 
sustained hypoxic event. Thus, the post-episode recovery time being limited, it is 
not possible to estimate whether there is a protective response to recurrent hypoxic 
events, but it is assumed that the vessels would suffer [43].
Therefore, in patients with OSA, there are lesions due to hypoxia and reperfu-
sion with increased lipid peroxidation. This process involves the oxidation of 
polyunsaturated fatty acids with the formation of reactive oxygen species and toxic 
products, having potential damaging effects for the brain and heart.
Also, in patients with vascular pathology, endothelial dysfunction is present. 
In patients with OSA, imbalances between vasoconstrictive mediators (higher 
thromboxane and endothelin levels) and vasodilators (nitric oxide, prostacycline) 
appear, and nitric oxide production has been shown to decrease in OSA. This 
imbalance predisposes to atherosclerosis [44]. Thus, the effects on cerebral flow, as 
well as hypoxia, may cause the onset of cerebral infarctions, resulting in vascular 
dementia. The presence of endothelial dysfunction, with the onset of neurocog-
nitive deficits, has been described even in studies performed in the paediatric 
population [16].
There are authors who consider that the cognitive impairment in OSA represents 
the short-term consequence of the poor quality of sleep manifested by daytime 
sleepiness or attention difficulties. Studies have shown specific and localized frontal 
lobe involvement, responsible for the executory dysfunction observed in OSA 
[45]. The basis of this hypothesis is that sleep disruption reduces the efficiency of 
restoration processes in the prefrontal cortex that will also lead to cellular and bio-
chemical stress. These processes, in turn, disrupt functional homeostasis, altering 
the viability of neuronal and glial cells [46–48]. The severity of sleep fragmentation 
is associated with attention deficit and decreased alertness, and the overall cogni-
tive deficit is the consequence of hypoxia. Due to sleep fragmentation, alteration of 
blood gases and changes of homeostasis in the frontal lobe and hippocampus leads 
to memory impairment and executory function deficiency.
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2.3 The effects of CPAP therapy on cognitive deficiency
A direct consequence of OSA, with impact on both personal and social levels, 
is the loss of vigilance. This increases the risk of traffic accidents in untreated 
patients, which is why it is important to diagnose and treat this condition as early 
as possible [49]. Election treatment of OSA is continuous positive airway pres-
sure (CPAP) therapy. This method was first described in 1981 [50]. Since then, 
technological progress has been made to suit the needs of patients. Also, in order to 
improve treatment adherence, device manufacturers have considered the impor-
tance of producing mask interfaces that match the user’s physiognomy. This variety 
improves comfort and reduces air leakage. The use of CPAP for at least 4 h of sleep 
during a 24-h period defines a minimum acceptable level in terms of a beneficial 
therapeutic response. Thus, for maximum benefit, most clinicians recommend 
using the device for the entire duration of sleep [51].
Canessa et al. studied the effects of CPAP therapy on neurocognitive changes 
in 17 OSA patients. Therefore, voxel-based morphometry determinations showed 
significant post-therapy improvements in the cognition level, together with the 
increase of the volume of the grey matter in the frontal lobe and hippocampus [52]. 
This is why early diagnosis and initiation of CPAP therapy could prevent, in the 
medium and long term, the cognitive impairment. In summary, this study provides 
the first evidence that structural brain abnormalities exist in hypoxemia-sensitive 
regions and they may change with treatment. These results suggest that even the 
negative neurological effects of hypoxemia can be reversed with consistent and 
complete treatment. Therefore, adherence to CPAP treatment can lead not only to 
clinical recovery but also to structural brain recovery. It should be noted that the 
patients in this study showed a positive response to treatment. MRI may thus be 
used as a marker, to evaluate the response to treatment [53].
There are studies that show that use of CPAP over 12 months also leads to signifi-
cant recovery of the impaired white matter, including corpus callosum, with impor-
tant impact on improving cognition [54]. There are also numerous studies evaluating 
the effects of CPAP therapy in stroke patients who develop OSA. The stroke can 
aggravate functional changes and cognition. A study conducted in Korea highlights 
the beneficial effects of the therapy and suggests that this treatment should be con-
sidered as part of the rehabilitation programme for stroke patients. Thereby, CPAP 
therapy applied to patients with subacute stroke for a relatively short period of time 
leads to an improvement in sleep quality, daytime sleepiness and cognitive function. 
Further research regarding the improvement of neurological and functional status 
among stroke patients, who have received long-term CPAP treatment, is needed [55].
In conclusion, although there are numerous studies that have focused on the 
association of OSA with cognitive deficits, things are far from fully elucidated. 
Variate and numerous comorbidities, including ageing, hypoxemia, genetic factors, 
strokes, etc., independently influence these deficits. Untreated OSA is correlated 
with changes in brain structure and function through cell death, grey matter 
destruction, inflammatory changes and decreased white matter integrity. Unlike 
other pathologies, however, initiating CPAP therapy as early as possible prevents 
the installation of the cognitive deficiency or improves it if it is already installed.
3. Cognitive impairment in chronic obstructive pulmonary disease
COPD is a common disease, characterized by persistent respiratory symptoms 
and airflow limitation caused by significant exposure to noxious particles and gases. 
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COPD is an important cause of morbidity and premature death. According to the 
WHO, by 2030 it will be the third cause of death worldwide [56].
A large meta-analysis which included 23,116 patients with COPD showed an 
alarming prevalence of MCI, up to 32%, compared with the prevalence of 10–20% 
in the general population [57]. Furthermore, in time this mild cognitive decline 
seems to aggravate, and these patients will have an increased risk to develop multi-
infarct dementia or Alzheimer’s disease [58].
3.1 Risk factors for cognitive impairment in patients with COPD
The origin of the cognitive impairment COPD patients is still not well estab-
lished. Several pathological relays can interfere: smoking, ageing, severe lung dis-
ease, hypoxemia, hypercapnia, systemic inflammation, oxidative stress, endothelial 
dysfunction, comorbidities, sedentary lifestyle and genetic factors.
3.2 Physiopathology of cognitive impairment in patients with COPD
From all the above, hypoxemia seems to be the most important risk factor. Not 
only continuous hypoxemia but also the intermittent one (during efforts, sleep and 
daily activities) can cause brain damage [59]. Moreover, a study showed that during 
COPD exacerbations when hypoxemia worsens, patients have significantly altered 
cognitive scores compared with those recorded in stable phases and age-matched 
controls [60]. Neurologic impairment also worsens with COPD progression. In 
the severe pulmonary disease, altered MMSE scores were reported in 64% of cases 
[61]. The most common abnormalities in the MMSE included construction (39%), 
attention (31%), verbal recall (26%), visuospatial orientation (24%) and language 
(13%). In tasks that required drawing (e.g. an analogue clock with a set time) or 
other tasks that required judgement, poor performance was associated with a higher 
mortality [62]. In addition, Chang et al. in a 3-year prospective study showed that 
the association between COPD and cognitive dysfunction led to increased disabil-
ity, hospital rate and mortality [63].
One of the most elaborate studies was performed by Dodd et al. [4] who focused 
on non-hypoxemic COPD patients and combined different brain function assess-
ment techniques such as magnetic resonance diffusion tensor imaging, resting 
state functional MRI and neuropsychological questionnaires. The report showed 
that these individuals had decreased integrity of the white matter, dysfunction of 
grey matter and poor performance in the cognitive questionnaires, compared with 
age-matched controls. The most significant deficits recorded through imaging 
techniques were poor executive function, low processing speed and episodic and 
working memory impairment, which all corresponded with the deficits seen on the 
MMSE test.
The Rotterdam Study used high-resolution MRI to evaluate cerebral structures 
in subjects with COPD and reported a higher frequency of cerebral microbleeds. 
This observation supports the concept of cerebral small-vessel disease that leads to 
cognitive decline via cerebral micro-bleeding areas. They also increased the MRI 
performance by introducing voxel-based morphometry analysis. Through this 
technique, they demonstrated for the first time that even stable COPD patients, 
who had subclinical cognitive impairment, presented grey matter volume altera-
tions on MRI [64].
Other MRI studies revealed a significantly loss of grey matter in numerous brain 
areas: precuneus, right inferior parietal lobule, right superior temporal gyrus/
middle temporal gyrus, hippocampus, limbic and paralimbic structures, cingulate, 
amygdala, etc. The common aspect in these studies is heterogeneity and broad 
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distribution of the lesions which could explain the multiple and variate neurologic 
manifestations these patients experience. Moreover, neuroimaging showed that 
parietal lobule and precuneus are also altered in Alzheimer’s disease.
The psychometric profile impairment correlates with variable components of 
COPD such as disease severity, exacerbations, hypoxemia or hypercapnia [58]. For 
accurate results it is indicated to use a battery of tests, not a single one. The most 
commonly affected cognitive domains are memory, attention, motor and executive 
function, naming ability and visuospatial orientation [65].
On the other hand, COPD cases without comorbidities are rare. This disease 
is frequently associated with both respiratory pathologies, like pulmonary 
hypertension (3–84%), obstructive sleep apnea (58–88%) or lung cancer 
(3–22%), and non-respiratory comorbidities such as systemic arterial hyper-
tension (14–71%), ischemic heart disease (4–68%), depression (12–49%) and 
diabetes mellitus type 2 (10–33%) [66]. Although the number of comorbidities 
rises with age, special caution should be addressed to cognitive-related comor-
bidities: cerebrovascular diseases, cardiovascular pathology, diabetes mellitus 
and sleep apnea syndrome. These pathologies should be managed according to 
current guidelines.
3.3  The effects of therapy and pulmonary rehabilitation on cognitive  
deficiency in COPD patients
Studies show that 50% of COPD patients abandon the prescribed inhaled 
medication and the oxygen therapy during the first year of therapy and just 25% 
use oxygen therapy for activities outside their house [67]. Moreover, older COPD 
patients and those with cognitive impairment have even lower adherence levels to 
inhalation therapy. The cognitive status impacts patient’s ability to recall when and 
how to use the inhaler devices. Poor executive functioning is often associated with 
a “knowing–doing” discrepancy [68]. All these factors listed above have a negative 
impact on treatment adherence and self-management.
The dyspnea–inactivity–muscular dysfunction circle developed by COPD 
patients will lead to isolation, depression and low adherence to pulmonary reha-
bilitation programmes. Given the multifactorial aspects of adherence and the high 
prevalence of MCI among COPD population, pulmonary rehabilitation pro-
grammes should be tailored to subject’s needs.
On the other hand, these programmes have a positive feedback on respiratory 
symptoms and neurologic function. Therefore, screening for these comorbidities 
should be considered during baseline pulmonary rehabilitation assessment [69]. 
Cognitive behavioural therapy or psychological support should be considered 
when psychological difficulties interfere with disease self-management and 
 adherence [67].
Another condition that should not be ignored in patients with COPD is gait 
impairment. More evidence suggests that muscle loss, reduced exercise capacity 
and functional mobility is leading to an important risk of falls. Interventions that 
include coordination, balance and strength training proved to be effective in older 
adults [70]. However, balance training and fall prevention strategies are still not 
mentioned by the pulmonary rehabilitation guidelines, and very few rehabilitation 
centres have a standardized balance assessment.
Although regular use of long-term oxygen therapy (LTOT) is correlated with a 
reduced risk of cognitive impairment in subjects with COPD, it is still under debate 
when and to whom it should be addressed. However, in patients who develop inter-
mittent hypoxemia (during effort or sleep), earlier oxygen supplementation should 
be considered in order to prevent irreversible neurologic damage [56].
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During COPD exacerbations in hypercapnic respiratory failure, non-invasive 
ventilation is a key management tool which markedly reduces mortality and mor-
bidity. Prompt initiation of CPAP therapy prevents the installation of the cognitive 
impairment [71].
4. Cognitive impairment in idiopathic pulmonary fibrosis
Pulmonary fibrosis describes the group of fibrosing interstitial lung diseases 
(ILDs) that causes progressive scarring of the alveolar interstitium, often leading to 
hypoxemic respiratory failure. ILDs encompass a large and varied group of paren-
chymal lung disorders, including diseases of unknown cause (idiopathic interstitial 
pneumonias), as well as those associated with other diseases (connective tissue 
disease-associated ILDs, chronic sarcoidosis) or environmental exposures (chronic 
hypersensitivity pneumonitis).
Idiopathic pulmonary fibrosis (IPF), the most extensively studied type of ILD, 
is a relentlessly progressive lung disease with a prognosis that can be worse than 
many cancers. With a median survival time of 2.5–3.5 years after diagnosis [72], 
IPF portends substantial morbidity and mortality outcomes, not all of which are 
directly related to the progressive fibrotic disease itself.
This older population with a median age of 66 years at diagnosis frequently 
experience various comorbidities, which influence the clinical spectrum, progres-
sion and mortality of the disease. An analysis of 272 IPF patients reported that 
58% of cases had one, two or three comorbid conditions, 30% had four to seven 
comorbid conditions and only 12% had no comorbidities [73]. Respiratory comor-
bidities, including emphysema (8–34%), obstructive sleep apnea (58–88%), lung 
cancer (3–22%) and pulmonary hypertension (3–84%), were common in many 
studies, although estimates vary widely depending on the source population. Non-
respiratory comorbidities such as gastro-oesophageal reflux (30–80%), systemic 
arterial hypertension (14–71%), ischaemic heart disease (4–68%), diabetes mellitus 
type 2 (10–33%) and depression (12–49%) are also highly prevalent [74, 75].
4.1 Risk factors for cognitive deficits in patients with IPF
Related to IPF or associated morbidity, there are several potential factors and 
conditions for the emergence of a cognitive deficit. Hypoxemia, a history of smok-
ing, ageing and chronic evolution of the disease are potential elements for the 
emergence of a cognitive deficit.
Difficulties in breathing (increased intrinsic elastic load of respiratory muscles 
and stimulation of peripheral mechanoreceptors) [76], night cough, drugs, hypox-
emia and obstructive apnea can all alter the quality of life.
4.2 Physiopathology of cognitive impairment in patients with IPF
IPF patients develop progressive ventilatory restriction and exercise intoler-
ance. Alteration of blood gases is a common feature in IPF pathophysiology. 
Patients experience transient or continuous hypoxia resulting in a substantial 
cumulative time with an SpO2 below 90%. Nocturnal hypoxia is common in 
chronic fibrotic interstitial lung diseases, both in patients who associate OSA, 
as those without this comorbidity. In the absence of OSA, nocturnal hypoxia 
could be a result of alveolar hypoventilation, altered ventilation-perfusion ratio 
and a desaturation trend, due to patients on the abrupt portion of the oxygen- 
haemoglobin dissociation curve [77, 78].
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Epidemiologic research has shown that besides genetic and environmental 
factors, such as lifestyles and cardiovascular risk factors, decreased lung func-
tion is also associated with dementia and cognitive impairment in the general 
population.
In a large population-based cohort enrolled in the Atherosclerosis Risk in 
Communities Study [79], the presence of a restrictive ventilatory pattern was 
associated with worse performance in cognitive assessments and with an increased 
risk of dementia hospitalization.
A recent prospective study [80] found that patients with restrictive lung disease 
have almost twice the chance of developing dementia or mild cognitive impairment 
as healthy individuals. Researchers followed more than 14.000 middle-aged people 
for over 23 years. Lung disease and impaired lung function were associated with 
greater risk of dementia and mild cognitive impairment through both Alzheimer’s 
disease and cerebrovascular aetiologies. Although both COPD and restrictive 
impairment were associated with increased risk of the dementia phenotypes, 
magnitudes of association were most pronounced for restrictive impairment. There 
were no differences between smokers and non-smokers.
Different pathogenic mechanisms could explain the association of lung function 
with cognitive performance and risk of dementia. Chronic hypoxia might lead to 
ischaemic brain injury and neurodegeneration as prospective studies have found 
that individuals with low lung function or reduced arterial oxygen saturation are 
more likely to develop white matter lesions and lacunar infarcts [81, 82].
A restrictive ventilatory pattern has been associated with the incidence of diabe-
tes and subclinical atherosclerosis and an increased risk of cardiovascular outcomes 
[83, 84]. In turn, diabetes and cardiovascular disease might cause cognitive impair-
ment and increase the risk of dementia.
Worse lung function might cause cognitive impairment and dementia through 
the development of a pro-inflammatory state. High levels of C-reactive protein, 
elevated in individuals with reduced lung function, have been associated with a 
higher risk of dementia [85, 86].
In IPF, a disease with a potential rapid and frequent development of hypoxemia, 
it is surprising that cognitive impairment has been investigated in very few studies.
In a limited study [87], with only seven IPF patients undergoing pulmonary 
rehabilitation, applying a battery of five psychometric tests (recall of verbal infor-
mation, sustained visual attention, efficiency in completing sequential tasks, verbal 
fluency, visuospatial and graphomotor proficiency) found impaired cognition only 
on the level of visual attention.
A prospective, observational study examining cognitive function in 30 IPF 
patients with normal oxygen saturations and comparing them to COPD and 
smoking controls demonstrated that almost half of IPF patients have mild cognitive 
dysfunction, unexplained by age [88].
In a prospective, cross-sectional, descriptive study [89], Bors et al. showed 
that individuals with severe IPF have worse cognitive function than those with 
mild-to-moderate disease and controls. Participants were evaluated through five 
neuropsychological tests that assessed various domains of cognitive function: speed 
for attention, sequencing, mental flexibility, visual search and motor function, 
information processing speed, selective attention, cognitive flexibility, executive 
function, assessment of verbal recall and recognition and specific cognitive deficits 
related to accessibility of lexical and semantic information. Severe IPF patients had 
a significantly inferior performance on tasks requiring speed-divided attention and 
slower processing speeds when requiring suppression of a familiar response. They 
are also more likely to have poorer health-related quality of life and symptoms of 
depression.
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A cross-sectional study aimed to assess cognition in IPF and to identify clini-
cal cognition modifiers, and 23 IPF patients were evaluated using the Montreal 
Cognitive Assessment (MoCA) [66]. As it has been previously mentioned, MoCA 
is a screening instrument with high specificity and sensitivity for detecting early 
cognitive impairments and is validated in multiple settings and disorders. MoCA 
evaluates several cognitive domains (short-term memory, visuospatial abilities, 
executive functioning, attention, concentration and working memory, language, 
orientation to time and place) to differentiate healthy cognitive ageing from 
mild cognitive impairment [90]. The study found a mild cognitive impairment in 
patients with IPF that is related to the areas of visuospatial abilities, language and 
working memory. Obstructive sleep apnea was highly prevalent in these patients 
(more than 80% of cases), and there was a significant correlation between cognitive 
function and the severity of apnea hypopnea index. Poor sleep quality is frequently 
met in IPF through sleep breathing disorders, including OSA, implying increased 
sleep fragmentation, decreased slow wave and REM sleep, as well as sleep oxygen 
desaturation [91].
4.3 Management of cognitive deficiency in IPF patients
Health-related quality of life is especially important in this patient population, 
given the lack of treatment options, poor mortality and rapid progression of the 
disease. The morbidity associated with IPF has a wide and profound impact on the 
patient’s quality of life. Therefore, cognition level and other patient-centred out-
comes are important goals to be evaluated in clinical research and practice. For IPF 
we do not currently have a specific cognitive assessment tool, so researchers have 
used validated tools in cognition analysis of other chronic respiratory diseases. The 
potential problem is that these tools cannot capture many of the effects of IPF on 
patients’ lives.
5. Conclusion
Patients with chronic respiratory conditions, such as obstructive sleep apnea, 
chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis, commonly 
associate cognitive impairment. Neurologic assessment should be included in the 
routine diagnostic algorithm of these conditions, in order to appreciate the overall 
impact of the disease, on patient’s quality of life and prognosis. Physicians who 
notice signs of memory loss, disorientation, gait impairment or even poor adher-
ence to pharmacologic/nonpharmacologic treatment, should screen their patients 
for cognitive dysfunction. For a better outcome, subjects who are identified with 
mild cognitive impairment by a screening tool should be referred for a thorough 
evaluation to a neurologist, and the chronic lung disease management should be 
tailored according to individual’s needs.
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